Purpose: To investigate the feasibility and safety of a novel minimally invasive adjustable-depth blunt injector for pharmaceuticals delivery into the posterior segment. Methods: Indocyanine green (ICG), sodium fluorescein and iron oxide nanoparticles (IONPs) were injected using the new injector into the extravascular spaces of the choroid (EVSC) compartment of rabbits and cadaver pig eyes. Spectral domain optical coherence tomography (SD-OCT), fundus imaging and histology analysis were performed for assessment of injection safety and efficacy. Results: Indocyanine green, fluorescein and IONPs were detected across the EVSC in rabbit eyes, covering over 80 per cent of the posterior eye surface. Injected IONPs were retained in the EVSC for at least 2 weeks following injection. No retinal detachment, choroidal haemorrhage or inflammation was detected in any of the injected eyes. In cadaver pig eyes, ICG was detected across the EVSC. Conclusions: This novel minimally invasive delivery system may be used to safely deliver large volumes of pharmaceuticals into a new treatment reservoir compartment -the EVSC which can serve as a depot, in close proximity to the retina, covering most of the surface of the back of the eye without insertion of surgical instruments under the central retina. This system is predicted to enhance the therapeutic effect of treatments for posterior eye disorders.
Introduction
Posterior segment diseases are the leading cause of irreparable visual impairment in industrialized countries. These include age-related macular degeneration (AMD), diabetic retinopathy (DR) and retinitis pigmentosa (RP). Age-related macular degeneration (AMD) and DR carry an especially heavy economic and social burden. With the ageing of population, the economical burden and social burden of these diseases are expected to rise (Wong et al. 2014) .
Treatment of posterior segment diseases is limited by the difficulty in delivering effective doses of drugs to the target tissues [retina, retinal pigmented epithelium (RPE) and choroid], due to the unique anatomical and physiological barriers of the eye (Thrimawithana et al. 2011; Kang-Mieler et al. 2014) . Thus, topical delivery is significantly limited by the corneal epithelium and the rapid and extensive precorneal loss that occurs as the result of drainage and tear fluid turnover. The bloodretina barrier limits the use of systemic application that may also be associated with significant side-effects (Duvvuri et al. 2003) . Intravitreal injections are currently being used in the clinic for delivery of certain pharmaceuticals (such as anti-angiogenic treatments). However, drugs injected directly into the vitreous are rapidly eliminated, necessitating frequent repeated injections that are not always well tolerated by patients and are associated with potential side-effects of retinal detachment, haemorrhage, endophthalmitis, increase in intraocular pressure (IOP), glaucoma and cataract (Brown et al. 2006; Janoria et al. 2007; Kim et al. 2008; Adelman et al. 2010; Bressler et al. 2015) . Furthermore, a recent study suggests that epiretinal membrane may act as a physical barrier, decreasing the penetration of the intravitreally injected drugs through these membranes, increasing the number of drug injections and decreasing injection intervals (Karaca et al. 2015) .
Intravitreal injection is less effective for delivery of advanced therapies such as stem cells and gene therapies, as cells and viral vectors diffuse poorly through the vitreous gel (Geroski & Edelhauser 2000; Thrimawithana et al. 2011; Rowe-Rendleman et al. 2014) . Injection of substances for sustained release of pharmaceuticals into the vitreous may be limited by interference with vision which is already markedly restricted (Manickavasagam & Oyewumi 2013) .
In recent clinical trials, cell and gene therapies were delivered into the posterior segment by subretinal injection (Schwartz et al. 2012 (Schwartz et al. , 2015 Boye et al. 2013) . However, the current subretinal injection method involves three-port pars-plana, vitrectomy and insertion of a needle that penetrates the retina and, in doing so, detaches the photoreceptor cell layer from the underlying RPE forming subretinal 'blebs' (Lu et al. 2009; Schwartz et al. 2012 Schwartz et al. , 2015 . Limited volumes can be injected, and therapeutic effect is restricted to areas proximal to point of injection (Maguire et al. 2008; Wright et al. 2010; Nork et al. 2012) . Moreover, the subretinal surgery raises a significant safety issue, as the retinal architecture across the entire retina in AMD and retinal degeneration patients is fragile and the surgery can induce mechanical damage, reactive gliosis and loss of function (Maguire et al. 2008; Nork et al. 2012) . These procedural effects were documented in a recent gene therapy trial in which patients receiving a subretinal injection under the foveal region demonstrated reduced retinal thickness and visual acuity (Jacobson et al. 2012) suggesting that subretinal surgery may present a significant risk in treating the foveawhich is the target location in AMD.
We developed a novel adjustabledepth blunt injector for minimally invasive delivery of therapeutics across the extravascular spaces of the choroid (EVSC) compartment that underlies the RPE, covering most of the surface of the back of the eye, including the central retina, without inserting any surgical tools under it. In previous studies, we demonstrated the safety and efficacy of delivering stem cells into the EVSC compartment using this novel injector (Rotenstreich et al. 2015) . In this study, we examined the efficacy and safety of delivering pharmaceuticals and nanotherapies into this compartment. As proof of concept, we used indocyanine green (ICG) dye and iron oxide nanoparticles (IONPs) , that are easily identified in histological analysis, and injected them into the EVSC of rabbits and cadaver pig eyes. The efficacy and safety of ICG and IONP delivery were examined.
Materials and Methods

Animals
Eighteen New Zealand White (NZW) rabbits were purchased from Harlan Laboratories, Rehovot, Israel and kept at the Sheba Medical Center animal facility. Sixteen porcine eyes were kept on ice and retrieved from the local abattoir within 4 hr post-mortem. All procedures and experiments were conducted with approval and under the supervision of the Institutional Animal Care Committee at the Sheba Medical Center, Tel-Hashomer, and conformed to recommendations of the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.
The minimally invasive adjustable-depth blunt injector
The novel injector includes two main components: a body with a standard syringe connector and a blunt-tipped hollow needle upwardly curved made of stainless steel (length 30 mm) with outer diameter dimensions of 100 lm (height) and 400 lm (width). The needle is associated with an extendible adjustable-length pin for forming a tract in the sub-RPE (Fig. 1A-C) . The pharmaceuticals were injected through a tapering tunnel through the sclera generated at a 20°towards the EVSC (Fig. 1D , blue arrows). The small hole at the end of tunnel having a diameter of about 400 lm created a one-way valve preventing backflow of the injected solution.
Injection of sodium fluorescein, ICG and IONPs
Five eyes of NZW rabbits were injected with a solution of 5% indocyanine green (ICG, Pulson Medical Systems SE, Germany). Two eyes of NZW rabbits were injected with a solution of 100 mg/ml sodium fluorescein (Fluoresceine Ò , Novartis Pharma AG, Basel, Switzerland). Eleven eyes of NZW rabbits were injected using the novel delivery system with a solution of 125 lg/ml iron oxide nanoparticles with a diameter of 15.0 AE 1.3 nm (Corem-Salkmon et al. 2012; Levy et al. 2015) . Rabbits were anesthetized with an intramuscular injection of ketamine (35 mg/kg) and xylazine (5 mg/kg). Injections were performed under a surgical microscope (Leica Wild M690; Wild Herring, Herring, Switzerland) . Following peritomy in the superior-temporal quadrant, a 3.0-mm linear tangential incision was preformed 4-mm posterior to the limbus using an AK diamond knife (Accutome Inc., Malvern, PA, USA). A scleral tunnel was generated (length of 3 mm) using a diamond keratome knife (Accutome Inc.) at an angle of 20°towards the choroid. The injector's pin was extended and inserted into the scleral tunnel to extend it. Then, 0.25 millilitres was injected. The procedure took 3-5 min. Rabbits were euthanized with sodium pentobarbital (140 mg/Kg), and the eyes were removed for histology analysis. Rabbits that were kept for follow-up received dipyrone in drinking water (1gr/l) for 12 hr after the injection. Rabbits were monitored for general health daily. Sixteen pig eyes were obtained from Lahav Animal Research Institute (Israel). The eyes were enucleated and transported in saline to the laboratory in a cool environment within 4 hr. Intraocular pressure was maintained by continuous irrigation via an anterior chamber maintainer. A bottle containing a balanced salt solution was positioned 50 cm above the eye, maintaining a steady IOP at 38 mmHg (Assia et al. 2007 ).
Histology analysis
For analysis of flat mounts of rabbit eyes, eyes were immersed in 4% paraformaldehyde (PFA) for 48 hr. A circumferential incision was made around the limbus followed by removal of the anterior segment, lens and vitreous body. Six cuts were made in the remaining eye cup, perpendicular to the edges resulting in a cloverleaf-like shape flat mount of the posterior segment. Percentage of stained area was performed using IMAGEJ (v, 1.48, National Institutes of Health, e198
Bethesda, MD, USA). Measurement of staining intensity was performed using IMAGEJ following a protocol described by McCloy et al. (2014) . Briefly, using IMAGEJ, the flat mount images were converted to 8-bit images. An outline was drawn around each sextant and the area, and integrated density was measured, along with several adjacent background readings. The total corrected sextant staining (TCSS) = integrated density -(area of selected sextant 9 mean staining of background readings), was calculated. Percentage of ICG stain in each sextant was calculated by the formula -TCSS of each sextant divided by summation of TCSS of all 6 sextants 9 100. Frozen sections were prepared by immersing the eyes in 4% PFA for 48 hr. Then, the eyes were infiltrated with a solution containing 2% PFA and 5% sucrose for 1 hr. Eyes were incubated in sucrose solutions (5%, 10%, 12.5% and 15% sucrose) for 30 min each followed by incubation in 20% sucrose for 16 hr and embedding in 20% sucrose in optimum cutting temperature (OCT, Sakura Finetek USA, Inc., Torrance, CA, USA). Twelve micrometer sections along the vertical meridian of the eye through the optic nerve were cut on a cryostat. For detection of injected nanoparticles, sections were stained with Prussian blue and counter-stained with nuclear fast red (both from Sigma-Aldrich Inc., St. Louis, MO, USA) (Levy et al. 2015) . For safety analysis, eyes were stained with haematoxylin and eosin.
Imaging of fluorescein injected into the EVSC compartment
Fluorescein imaging was performed using Zeiss FF450plus IR camera (Carl Zeiss Meditec AG, Jena, Germany) before and immediately following fluorescein injection into the EVSC. The rabbit corneas were kept moist with 2.5% hydroxypropyl methylcellulose.
Spectral domain optical coherence tomography (SD-OCT)
Rabbits were anesthetized with an intramuscular injection of ketamine (35 mg/kg) and xylazine (5 mg/kg), and their pupils were dilated by topical administration of 1 drop of 0.5% tropicamide eye drops (Fisher Pharmaceuticals Labs, Bnei Brak, Israel) before image acquisition. Corneas were kept moist with 2.5% hydroxypropyl methylcellulose (Fisher Pharmaceuticals Labs). Eyes were subjected to OCT imaging with Spectralis Ò Multicolor OCT (Heidelberg Engineering, Heidelberg, Germany). Rabbits were placed on a platform with the visual streaks (3 mm ventral to the optic nerve head, ONH) located at the centre of the image. Duration of the procedure was approximately 15 min per eye. We performed rectangular scans with 768 A-scan per B-scan, with a total of 25 B-scan per frame. The SPECTRALIS TruTrack TM active eye tracking and AutoRescan procedures were used for rescanning at the exact same location of the retina as the baseline examination. Spectral domain optical coherence tomography scans were analysed using IMAGEJ (version 1.5d; National Institutes of Health, Bethesda, MD, USA), registering 7 Bscans per image using the Stackreg plug-in (Orhan et al. 2015) . Thickness of the following layers was measured: retinal nerve fibre layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), RPE, choroid and sclera, ORL -outer retinal layer. Total retina thickness was measured from RNFL to ORL.
Intraocular pressure measurement
Intraocular pressure (IOP) measurements were performed using a 
Results
Injection of ICG and sodium fluorescein across the EVSC compartment of rabbit eyes
To examine the feasibility of using the novel injection system for delivery of pharmaceuticals into the posterior segment, 250 ll of a solution of ICG dye was injected using the device into rabbit eyes. Figure 2A demonstrates a wide angle (102 degrees) SPECTRA-LIS Ò fundus imaging of a rabbit eye before and immediately following ICG injection at the superior quadrant. Injected ICG covered nearly 80% of the retina. A flat mount of the eye removed immediately after imaging demonstrated staining of 90% of the posterior segment surface area (Fig. 2B) . Quantification of staining intensity revealed that injected ICG was distributed nearly evenly throughout the posterior segment, with 14-18% of dye in each flat mount sextant (Fig. 2C) . Cross sections of the retina demonstrated that injected ICG was localized in the choroid layer (Fig. 2D) . Multicolour fundus imaging revealed that ICG staining was localized between the choroidal blood vessels (Fig. 3 A,B) .
Next we injected sodium fluorescein into the EVSC of rabbit eyes. Fundus imaging revealed no fluorescein signal prior to injection (data not shown). Following injection into the EVSC, a clear fluorescein signal was evident between the choroidal blood vessels throughout the fundus image (Fig. 3C) . Figure 4 shows a mosaic of histological sections of a rabbit eye removed 3 hr following injection of ICG. Indocyanine green staining (green) was clearly demonstrated across the EVSC compartment, covering length of 2643 AE 491 lm (mean AE SD), 72 AE 7% (mean AE SD) of the total circumference of the back of the eye. No ICG staining was observed in the contralateral control eyes (data not shown).
Injection of IONPs across the EVSC compartment of rabbit eyes
Next we tested the injection of narrowsize (15.0 AE 1.3 nm in diameter)
IONPs into the EVSC using the novel injection system. These nanoparticles were chosen as proof of concept for delivering nanotherapeutics using the new delivery system. The iron oxide enables easy detection of the nanoparticles in the target tissue using Prussian blue staining (Levy et al. 2015) . Two hundred and fifty microlitres of IONP solution was injected into rabbit eyes. Frozen sections were stained with Prussian blue iron staining and counterstained with nuclear fast red. As shown in Fig. 5 , a thin sub-RPE layer was positively stained with Prussian blue covering 2482 AE 933 lm (mean AE SD), 69 AE 13% (mean AE SD) of the circumference of the back of the eye. No positive staining was observed in the contralateral control eyes (data not shown and Fig. 6A,B) . Furthermore, IONPs were clearly demonstrated in the extravascular spaces of the choroid in rabbit eyes removed 7 and 14 days following injection (Fig. 6C,D) .
SD-OCT imaging
Safety of the injection procedure was evaluated using SD-OCT imaging. Representative SD-OCT images taken at the inferior temporal quadrant prior to injection, 10 min and 2 days following injection of ICG, are presented in 
IOP measurement
Changes in IOP in control and injected eyes were determined at different timepoints following IONP injection in three rabbits. The IOP was increased immediately (1 min, Fig. 8 ) following injection of IONPs compared to baseline measurements [(33.49 mmHg [SE = 15. 14] versus 9.85 mmHg [SE = 1.58], p = 0.19). After 5 min, the IOP in the injected eye was markedly decreased (16.13 AE 8.97 mmHg, mean AE SE) and 10 min following injection, the IOP returned to the baseline level (11.5 AE 4.5 mmHg, p = 0.7). No significant changes in IOP were recorded in the control non-injected eyes compared to baseline measurements (all p > 0.05).
Histopathology analysis of injected eyes
To further evaluate the safety of the new injector, sections were stained with haematoxylin-eosin and examined by a pathologist. No gross or microscopic changes or inflammatory reaction were observed in any of the eyes injected with either ICG or IONPs.
Injection of ICG dye across the subretina of cadaver pig eyes
To demonstrate the efficacy of the new delivery system in pig eyes, cadaver pig eyes were injected with ICG dye. As shown in Fig. 9 , ICG dye was identified across the subretina and EVSC compartment in cadaver pig eyes.
Discussion
For years, the challenges in drug delivery to the posterior segment have proven difficult to overcome, limiting both the efficacy of available treatments as well as the development of new advanced therapeutics for posterior segment diseases (Kang-Mieler et al. 2014) . In this study, we used a novel delivery system that allows introduction of pharmaceuticals across the EVSC compartment with no retinal detachment, choroidal haemorrhage or inflammation. Our findings suggest that this system may potentially be used for safe and efficient delivery of pharmaceuticals for treatment of posterior segment diseases, many of which are incurable blinding diseases.
In the surgical procedure presented here, the triangular scleral tunnel formed a tract parallel to the retina and functioned as a one-way valve. The tunnel allowed the injected solution to flow in a high flow rate from the injector into the EVSC without reflux towards the central retina, leading to a nearly homogenous distribution of the injected materials along the vector of injection across the EVSC in rabbit and cadaver pig eyes. Prevention of back flow may also minimize extra-scleral toxicity concerns. Generation of the tunnel at an acute angle towards the choroid led to distribution of the injected pharmaceuticals in circumferential vector, covering over 80% of the posterior segment and presents a lower depth sensitivity compared to a perpendicular cut, which may increase injection safety by reducing the chance of penetrating the very thin layers of the choroid and retina. In addition, the acute angle facilitated the immediate spreading of the pharmaceuticals with no formation of a choroidal 'bleb'. The high flow rate generated in our system facilitated spreading of the injected solution across the EVSC and the one-way-valve mechanism prevented any backflow. The ocular pressure RNFL, retina nerve fibre layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium; ORL, outer retina layer.
Comparison of retinal thickness measurements (in lm) using SD-OCT in rabbit eyes before (baseline), and at indicated time-points (10 min, 2 days) following injection of 250 ll of ICG solution. All data are presented as mean AE SE from three rabbits at each time point at the same area. Student's t-test was used to evaluate differences between retinal thickness measurements at base line and at later time points. Total retina was measured from RNFL to ORL.
equilibrium further pressed the solution towards the periphery and facilitated better sealing of the scleral tunnel which served as a one-way valve. Numerous studies reported a transient increases in IOP after intravitreal injections (Brown et al. 2006; Bakri et al. 2009; Adelman et al. 2010; Pang et al. 2015) . For example, Brown et al. reported that 8% of 423 AMD patients receiving intravitreal injections of ranibizumab demonstrated a postinjection intraocular pressure of 30 mmHg or more (Brown et al. 2006) . In a study by Kim et al. with 120 eyes, 44-88% of eyes demonstrated IOP of 30 mm Hg or higher immediately after drug intravitrous injection, depending on volume injected (range 0.05-0.1 ml) and needle gauge (Kim et al. 2008 ). Bakri et al. reported that one-third of 178 patients injected with intravitreal triamcinolone, pegaptanib or bevacizumab demonstrated an IOP rise >10 mmHg within 30 min after injection of drugs (Bakri et al. 2009 ). Demirel et al. reported in a study of 202 eyes that 23.3% had IOP of >21 mmHg, 30 min after a first injection of ranibizumab (Demirel et al. 2015) . Moreover, recent studies suggest that repeated intravitreous injections of antivascular endothelial growth factor for diabetic macular oedema and AMD cause sustained elevation of IOP and may potentially increase the risk of glaucoma (Brown et al. 2006; Bakri et al. 2009; Adelman et al. 2010; Pang et al. 2015) . By contrast, in our study, a significantly larger volume was injected into rabbit eyes (250 ll). A non-significant increase with a mean of 24 mmHg was recorded immediately after injection, but IOP returned to baseline levels within 10 min. This short term and relatively small increase in IOP may be explained by the absorption of the injected solution in the EVSC matrix. In future studies, we will monitor the IOP following repeated injections in a larger number of rabbits as well as the safety and efficacy of drug injection in live pigs that closely resemble the human eye in terms of size and structure.
The novel posterior pole delivery system enables for the first time to inject large volumes (250 ll) under the retina, targeting a new compartmentthe EVSC. Injected treatment covers most of the area of the back of the eye including the central retina without insertion of any surgical tools near the macula, penetration of the retina or choroid. The procedure is very quick (3-5 min), requires minimal training and may facilitate minimally invasive and safe delivery of advanced therapeutics (including cells, gene therapy and nanotherapies) in close proximity to the target tissues (sub-RPE, choroid and supra-choroid). As the novel injector enables delivery of pharmaceuticals directly across the EVSC, it is predicted that it will enhance the efficacy of treatments for choroid-associated diseases, including anti-angiogenic therapy for neovascular AMD, chemotherapy for choroidal metastasis and treatments for choroidal inflammation (choroiditis), such as steroid therapy. Our future studies will be aimed at examining this prediction.
Our data suggest that injected IONPs are maintained in the EVSC for at least 2 weeks following injection. As both 'dry' AMD (geographic atrophy) and neovascular AMD involve disruption to the Bruch's membrane and RPE cell loss (van Lookeren Campagne et al. 2014) , we hypothesize that pharmaceuticals injected into the EVSC compartment may reach the overlaying retina through these gaps in the RPE and Bruch's membrane. This hypothesis is supported by our recent studies demonstrating that transplanting mesenchymal stem cells that secrete neurotrophic factors in the EVSC ameliorated retinal degeneration in a rat model of dry AMD (Tzameret et al. 2014 ). In the pig eyes, some ICG staining appeared in the subretina, most likely due to the use of cadaver eyes. Future studies will include evaluation of safety and efficacy of delivering therapeutics into the EVSC in live pigs. In addition, future studies will be aimed at determining the concentration gradients and pharmacokinetic profiles of several drugs in rabbit and pig eyes, prior to clinical trials. We are currently testing the feasibility of using this system for sustained release drug delivery technologies (such as light-activated in situ gels and polymeric gels and nanoparticles).
This study and our previous work (Rotenstreich et al. 2015) suggest that the novel injection system may potentially be used for safe and efficient delivery of cell therapy and pharmaceuticals into the posterior pole, in close proximity to the target retina and choroid. Our platform may enable new, more efficient treatment for posterior segment diseases.
